My injection record
Printed from glp1injectionsites.com
Where did you
inject today?
Keep your own record of the area and the day. It stays on this device.
Choose your medicine above. The body appears here, with the areas its label names shaded.
AbdomenThigh
Upper arm
- Chosen, not recorded yet
- Last recorded
- Earlier record
- Area the label names
No area chosen
Choose an area on the body, or by name below.
Your record
Nothing recorded yet.
Kept in this browser, on this device. We never receive your entries. On iPhone, Safari can clear a site’s saved data after seven days of using Safari without visiting that site. Adding this site to your Home Screen avoids that.
Calendar reminder, and clear my record
Calendar reminder
A repeating event for your own calendar. It does not name your medicine.
Start over
Deletes your record and settings from this browser.
What the label says about rotating
Choose your medicine to see what its label says.
What each label says
The eight FDA labels this site quotes all name the same three areas: the stomach area (abdomen), the thigh and the upper arm. All eight say to change the injection site rather than reuse the same spot. They differ on the details: six say someone else should inject the upper arm, for at least one of their devices, and four give a distance from the belly button. FDA lists Bydureon BCise as discontinued (Drugs@FDA, checked November 10, 2026); its label is still on DailyMed and quoted here.
Every quote on this page is checked word for word against the medicine's label on DailyMed, the National Library of Medicine's label database. Last checked November 10, 2026. Where a label has more than one set of Instructions for Use, the document is named under the quote.
| Medicine | Where the label says to inject | Upper arm | Belly button | FDA status | Label |
|---|---|---|---|---|---|
| Ozempicsemaglutide, weekly | “Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm.” | “Back of upper arm (only with help from someone else)” | “Stomach area (abdomen) at least 2 inches from the belly button.” | Not on FDA’s drug shortage list (checked November 10, 2026). | DailyMed |
| Wegovysemaglutide, weekly | “Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm.” | “back of upper arm (only with help from someone else).” | “lower stomach (keep 2 inches away from your belly button)” | Not on FDA’s drug shortage list (checked November 10, 2026). | DailyMed |
| Mounjarotirzepatide, weekly | “Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm.” | “Another person should give you the injection in the back of your upper arm.” | “You or another person can inject the medicine in your thigh or stomach (abdomen) at least 2 inches from the belly button.” | Not on FDA’s drug shortage list (checked November 10, 2026). | DailyMed |
| Zepboundtirzepatide, weekly | “Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.” | “Another person should give you the injection in the back of your upper arm.” | “You or another person can inject the medicine in your thigh or stomach (abdomen) at least 2 inches from the belly button.” | Not on FDA’s drug shortage list (checked November 10, 2026). | DailyMed |
| Trulicitydulaglutide, weekly | “Inject TRULICITY subcutaneously in the abdomen, thigh, or upper arm.” | “Another person should give you the injection in the back of your upper arm.” | Not stated | Not on FDA’s drug shortage list (checked November 10, 2026). | DailyMed |
| Bydureon BCiseexenatide extended-release, weekly | “Inject BYDUREON BCISE under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.” | No rule on who injects it | Not stated | DiscontinuedFDA lists it as discontinued (Drugs@FDA, application NDA209210, checked November 10, 2026). Its label page is still on DailyMed. Drugs@FDANot on FDA’s drug shortage list (checked November 10, 2026). | DailyMed |
| Victozaliraglutide, daily | “Inject VICTOZA subcutaneously in the abdomen, thigh or upper arm.” | “Choose your injection site in either the stomach (abdomen), thigh, or upper arm (only if caregiver administered)” | Not stated | In shortageOn FDA’s drug shortage list, limited availability (updated September 22, 2026): “Estimated shortage duration: TBD”. | DailyMed |
| Saxendaliraglutide, daily | “Inject SAXENDA subcutaneously in the abdomen, thigh, or upper arm.” | No rule on who injects it | Not stated | To be discontinuedOn FDA’s drug shortage list, limited availability (updated September 22, 2026): “Product will be available until discontinuation in January 2027”. Also listed as to be discontinued (updated August 25, 2026). | DailyMed |
Scroll sideways to see every column.
Supply status checked November 10, 2026; marketing status from Drugs@FDA, checked November 10, 2026. Source: FDA Drug Shortages database, via openFDA. Do not rely on openFDA to make decisions regarding medical care; check with your pharmacy.
How these labels have changed since January 2024: the label change record.
Full label guides: Mounjaro and Zepbound · Wegovy · Ozempic.
Victoza and Saxenda are taken daily; the others weekly. For the calendar reminder, the tracker sets the repeat to match the medicine you choose.
Common questions, answered from the labels
Can the same area be used again?
All eight labels describe changing the spot within the same area or region.
- Ozempic: “Instruct patients to use a different injection site each week when injecting in the same body region.”
- Wegovy: “You may inject in the same body area each week, but make sure it is not in the same spot each time.”
- Mounjaro: “Change (rotate) your injection site each week. You may use the same area of your body but be sure to choose a different injection site in that area.”
- Zepbound: “Change (rotate) your injection site each week. You may use the same area of your body but be sure to choose a different injection site in that area.”
- Trulicity: “Change (rotate) your injection site each week. You may use the same area of your body, but be sure to choose a different injection site in that area.”
- Bydureon BCise: “Each week you can use the same area of your body, but choose a different injection site in that area of your body.”
- Victoza: “Rotate injection sites within the same region in order to reduce the risk of cutaneous amyloidosis”
- Saxenda: “Rotate injection sites within the same region in order to reduce the risk of cutaneous amyloidosis”
Who injects the upper arm?
Every label names the upper arm. Six add a rule about who injects it, for at least one of their devices.
- Ozempic: “Back of upper arm (only with help from someone else)”
- Wegovy: “back of upper arm (only with help from someone else).”
- Mounjaro: “Another person should give you the injection in the back of your upper arm.”
- Zepbound: “Another person should give you the injection in the back of your upper arm.”
- Trulicity: “Another person should give you the injection in the back of your upper arm.”
- Victoza: “Choose your injection site in either the stomach (abdomen), thigh, or upper arm (only if caregiver administered)”
Bydureon BCise and Saxenda name the upper arm with no rule about who injects it.
How far from the belly button?
Four labels give a distance.
- Ozempic: “Stomach area (abdomen) at least 2 inches from the belly button.”
- Wegovy: “lower stomach (keep 2 inches away from your belly button)”
- Mounjaro: “You or another person can inject the medicine in your thigh or stomach (abdomen) at least 2 inches from the belly button.”
- Zepbound: “You or another person can inject the medicine in your thigh or stomach (abdomen) at least 2 inches from the belly button.”
Trulicity, Bydureon BCise, Victoza and Saxenda do not state one.
Can it go in the same area as insulin?
Five labels address this, in nearly the same words.
- Ozempic: “It is acceptable to inject OZEMPIC and insulin in the same body region, but the injections should not be adjacent to each other.”
- Mounjaro: “It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.”
- Trulicity: “It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.”
- Bydureon BCise: “It is acceptable to inject BYDUREON BCISE and insulin in the same body region, but the injections should not be adjacent to each other.”
- Victoza: “It is acceptable to inject VICTOZA and insulin in the same body region but the injections should not be adjacent to each other.”
Wegovy, Zepbound and Saxenda do not address it.
For clinics and pharmacies
A version of this tracker and the printable rotation chart with your practice's name and logo, to hand to the patients you start on an injectable GLP-1. We set it up for you. One flat price of $49, no subscription.
Opens your email. Please do not include any patient information.